Search: WFRF:(Green Henrik) >
Real world evidence...
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
-
- Blomstrand, Hakon (author)
- Linköpings universitet,Avdelningen för Kirurgi, Ortopedi och Onkologi,Medicinska fakulteten,Region Östergötland, Klinisk patologi,Ryhov Cty Hosp, Sweden
-
- Scheibling, Ursula (author)
- Ryhov Cty Hosp, Sweden
-
- Bratthall, Charlotte (author)
- Kalmar Cty Hosp, Sweden
-
show more...
-
- Green, Henrik (author)
- Linköpings universitet,Avdelningen för läkemedelsforskning,Medicinska fakulteten,Natl Board Forens Med, Dept Forens Genet and Forens Toxicol, S-58758 Linkoping, Sweden
-
- Elander, Nils (author)
- Linköpings universitet,Avdelningen för Kirurgi, Ortopedi och Onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US
-
show less...
-
(creator_code:org_t)
- 2019-01-08
- 2019
- English.
-
In: BMC Cancer. - : BMC. - 1471-2407. ; 19
- Related links:
-
https://liu.diva-por... (primary) (Raw object)
-
show more...
-
https://bmccancer.bi...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- BackgroundIn the recent phase III trial MPACT the combination of gemcitabine and nab-paclitaxel (Gem/NabP) showed increased overall survival compared to gemcitabine alone in the treatment of advanced pancreatic ductal adenocarcinoma (aPDA). Until now there has been limited information on the clinical benefit and toxicity of the combination regimen in a real world setting. In addition the value for patients with locally advanced rather than metastatic aPDA has been unclear, since the former category of patients was not included in the MPACT trial.MethodsA multicentre retrospective observational study in the South Eastern Region of Sweden was performed, with the first 75 consecutive patients diagnosed with aPDA (both locally advanced and metastatic disease) who received first-line treatment with Gem/NabP.ResultsIn the overall population median progression free survival (PFS) and overall survival (OS) were 5.2 (3.4-7.0 95% CI) and 10.9 (7.8-14.0 95% CI) months, respectively. Patients with metastatic disease displayed a median OS of 9.4 (4.9-13.9) and a median PFS of 4.5 (3.3-5.7) months whereas the same parameters in the locally advanced subgroup were 17.1 (7.6-26.6) and 6.8 (5.2-8.4) months, respectively. Grade 3-4 hematologic toxicity was recorded: Neutropenia, leukopenia, thrombocytopenia, and anaemia were observed in 23, 20, 5, and 4% of patients, respectively. Dose reductions were performed in 80% of the patients.ConclusionThis study confirms the effectiveness and safety of first-line Gem/NabP in both locally advanced and metastatic PDA in a real world setting.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- Pancreatic cancer; Chemotherapy; Gemcitabine; Nab-paclitaxel; Bone marrow toxicity
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
-
BMC Cancer
(Search for host publication in LIBRIS)
To the university's database